公开(公告)号：US06979563B1

公开(公告)日：2005-12-27

申请号：US09715965

申请日：2000-11-17

Applicant: Elizabeth M. Denholm ,  Yong-Qing Lin ,  Paul J. Silver

Inventor： Elizabeth M. Denholm ,  Yong-Qing Lin ,  Paul J. Silver

IPC: A61K38/51 ,  C12N9/00

CPC classification number: A61K38/51

Abstract: A highly purified and specific glycosaminoglycan degrading enzyme, chondroitinase AC, and to a lesser extent, chondroitinase B, can be used in the treatment of metastatic cancers and in other disorders characterized by angiogenesis. The enzymatic removal of chondroitin sulfates A and C, and to a lesser extent, chondroitin sulfate B, from cell surfaces directly decreases the ability of tumor cells to invade blood vessels and thus prevents the formation of metastatic, or secondary tumors; inhibits tumor cell growth; and decreases angiogenesis by inhibiting both endothelial cell proliferation and capillary formation. Decreasing the formation of new blood vessels into the tumor in turn decreases the potential for tumor growth, and further decreases the ability of tumor cells to invade the bloodstream. These effects are opposite to the prometastatic effects of tumor-secreted heparanase.

Abstract translation: 高度纯化和特异性的糖胺聚糖降解酶，软骨素酶AC和较小程度的软骨素酶B可用于治疗转移性癌症和其它以血管生成为特征的疾病。 来自细胞表面的硫酸软骨素A和C以及较低程度的硫酸软骨素酶的酶促去除直接降低肿瘤细胞侵入血管的能力，从而防止转移性或继发性肿瘤的形成; 抑制肿瘤细胞生长; 并通过抑制内皮细胞增殖和毛细血管形成来减少血管生成。 减少肿瘤新血管的形成反过来降低了肿瘤生长的可能性，进一步降低了肿瘤细胞侵入血液的能力。 这些作用与肿瘤分泌型肝素酶的前体作用相反。